Supernus Pharmaceuticals (SUPN) Stock Forecast, Price Target & Predictions
SUPN Stock Forecast
Supernus Pharmaceuticals stock forecast is as follows: an average price target of $38.00 (represents a 6.09% upside from SUPN’s last price of $35.82) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SUPN Price Target
The average price target for Supernus Pharmaceuticals (SUPN) is $38.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $36.00. This represents a potential 6.09% upside from SUPN's last price of $35.82.
SUPN Analyst Ratings
According to 3 Wall Street analysts, Supernus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SUPN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Supernus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | David Amsellem | Piper Sandler | $36.00 | $33.49 | 7.49% | 0.50% |
| May 24, 2024 | David Amsellem | Piper Sandler | $41.00 | $27.84 | 47.24% | 14.46% |
| Apr 08, 2024 | Irene Buhalo | Jefferies | $40.00 | $32.27 | 23.97% | 11.67% |
| Apr 08, 2024 | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | 17.77% | 6.09% |
The latest Supernus Pharmaceuticals stock forecast, released on Sep 11, 2024 by David Amsellem from Piper Sandler, set a price target of $36.00, which represents a 7.49% increase from the stock price at the time of the forecast ($33.49), and a 0.50% increase from SUPN last price ($35.82).
Supernus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $36.00 | $38.75 |
| Last Closing Price | $35.82 | $35.82 | $35.82 |
| Upside/Downside | -100.00% | 0.50% | 8.18% |
In the current month, the average price target of Supernus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Supernus Pharmaceuticals's last price of $35.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 18, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 10, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 08, 2024 | Jefferies | Buy | Buy | Hold |
Supernus Pharmaceuticals's last stock rating was published by Cowen & Co. on Oct 18, 2024. The company gave SUPN a "Buy" rating, the same as its previous rate.
Supernus Pharmaceuticals Financial Forecast
Supernus Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $153.88M | $135.56M | $153.76M | $167.33M | $177.35M | $170.05M | $152.51M | $159.05M | $148.46M | $141.33M | $130.93M | $143.56M | $155.13M | $126.73M | $94.98M | $100.45M | $102.14M | $104.69M | $85.47M | $90.43M | $57.58M |
| Avg Forecast | $167.70M | $161.23M | $152.23M | $141.83M | $154.51M | $157.35M | $148.83M | $145.83M | $155.03M | $146.17M | $143.63M | $139.02M | $180.33M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $60.90M | $66.67M |
| High Forecast | $172.87M | $166.21M | $156.93M | $144.84M | $158.15M | $157.66M | $148.83M | $145.83M | $158.10M | $146.19M | $148.06M | $143.31M | $185.89M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $73.08M | $80.00M |
| Low Forecast | $162.95M | $156.66M | $147.92M | $138.82M | $152.18M | $157.04M | $148.83M | $145.83M | $152.31M | $146.15M | $139.56M | $135.08M | $175.21M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $48.72M | $53.33M |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 0.94% | 1.11% | 0.93% | 1.03% | 1.04% | 0.99% | 1.03% | 1.04% | 1.04% | 1.01% | 0.98% | 1.18% | 1.28% | 1.14% | 0.94% | 0.94% | 0.96% | 0.84% | 1.48% | 0.86% |
Supernus Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $155.03M, with a low forecast of $152.31M, and a high forecast of $158.10M. SUPN's average Quarter revenue forecast represents a 0.75% increase compared to the company's last Quarter revenue of $153.88M (Sep 23).
Supernus Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $31.29M | $-17.59M | $28.84M | $55.03M | $22.41M | $34.52M | $37.97M | $20.69M | $41.56M | $43.32M | $23.62M | $51.31M | $66.38M | $56.34M | $36.52M | $48.41M | $45.70M | $50.08M | $32.67M | $34.31M | $18.01M |
| Avg Forecast | $49.71M | $47.79M | $45.12M | $42.04M | $45.80M | $46.64M | $44.11M | $43.62M | $45.95M | $43.33M | $42.57M | $39.65M | $56.11M | $49.34M | $46.95M | $36.05M | $44.34M | $40.66M | $38.74M | $32.77M | $41.82M | $37.48M | $28.26M | $22.96M | $30.62M | $31.09M | $31.26M | $41.70M | $19.44M | $20.47M |
| High Forecast | $51.24M | $49.27M | $46.52M | $42.93M | $46.88M | $46.73M | $44.11M | $52.34M | $46.86M | $43.33M | $43.89M | $47.58M | $67.34M | $49.34M | $46.95M | $43.26M | $44.34M | $40.66M | $38.74M | $39.32M | $41.82M | $37.48M | $28.26M | $27.55M | $30.62M | $31.09M | $31.26M | $50.04M | $23.33M | $24.56M |
| Low Forecast | $48.30M | $46.44M | $43.84M | $41.15M | $45.11M | $46.55M | $44.11M | $34.89M | $45.15M | $43.32M | $41.37M | $31.72M | $44.89M | $49.34M | $46.95M | $28.84M | $44.34M | $40.66M | $38.74M | $26.22M | $41.82M | $37.48M | $28.26M | $18.36M | $30.62M | $31.09M | $31.26M | $33.36M | $15.55M | $16.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.72% | -0.41% | 0.73% | 0.98% | 0.45% | 0.74% | 1.05% | 0.47% | 1.02% | 1.12% | 0.72% | 1.23% | 1.77% | 1.99% | 1.59% | 1.58% | 1.47% | 1.60% | 0.78% | 1.76% | 0.88% |
3 analysts predict SUPN's average Quarter EBITDA for Dec 23 to be $45.95M, with a high of $46.86M and a low of $45.15M. This is 46.86% upper than Supernus Pharmaceuticals's previous annual EBITDA (Sep 23) of $31.29M.
Supernus Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-15.98M | $-831.00K | $16.95M | $25.48M | $1.75M | $7.87M | $25.62M | $2.44M | $21.56M | $23.73M | $5.69M | $30.77M | $40.00M | $34.67M | $21.52M | $33.13M | $28.86M | $32.73M | $18.34M | $26.35M | $10.30M |
| Avg Forecast | $30.81M | $28.57M | $24.46M | $22.03M | $28.01M | $24.83M | $21.85M | $10.52M | $31.00M | $280.08K | $11.76M | $9.56M | $33.65M | $19.88M | $16.16M | $8.69M | $16.16M | $15.46M | $13.51M | $7.90M | $31.34M | $19.36M | $24.38M | $13.53M | $32.99M | $34.10M | $33.35M | $23.41M | $14.93M | $11.70M |
| High Forecast | $32.04M | $29.71M | $25.44M | $23.87M | $30.81M | $25.22M | $22.72M | $12.62M | $33.26M | $291.31K | $12.24M | $11.47M | $40.38M | $19.88M | $16.16M | $10.43M | $16.16M | $15.46M | $13.51M | $9.48M | $31.34M | $19.36M | $24.38M | $16.23M | $32.99M | $34.10M | $33.35M | $28.10M | $17.92M | $14.04M |
| Low Forecast | $29.67M | $27.52M | $23.56M | $20.20M | $25.21M | $24.45M | $21.04M | $8.41M | $28.73M | $269.76K | $11.33M | $7.65M | $26.92M | $19.88M | $16.16M | $6.95M | $16.16M | $15.46M | $13.51M | $6.32M | $31.34M | $19.36M | $24.38M | $10.82M | $32.99M | $34.10M | $33.35M | $18.73M | $11.95M | $9.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | -57.04% | -0.07% | 1.77% | 0.76% | 0.09% | 0.49% | 2.95% | 0.15% | 1.39% | 1.76% | 0.72% | 0.98% | 2.07% | 1.42% | 1.59% | 1.00% | 0.85% | 0.98% | 0.78% | 1.76% | 0.88% |
Supernus Pharmaceuticals's average Quarter net income forecast for Jun 23 is $11.76M, with a range of $11.33M to $12.24M. SUPN's average Quarter net income forecast represents a -30.59% decrease compared to the company's last Quarter net income of $16.95M (Mar 23).
Supernus Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $82.70M | $86.78M | $85.60M | $73.97M | $112.31M | $100.48M | $90.46M | $101.73M | $72.03M | $69.53M | $61.46M | $56.30M | $54.66M | $48.10M | $42.88M | $35.73M | $40.65M | $41.08M | $40.97M | $36.85M | $28.24M |
| Avg Forecast | $81.62M | $78.48M | $74.10M | $69.03M | $75.21M | $76.59M | $72.44M | $113.50M | $75.46M | $71.15M | $69.91M | $103.18M | $61.57M | $83.95M | $79.89M | $93.80M | $75.44M | $69.17M | $65.91M | $85.27M | $71.16M | $63.76M | $48.07M | $26.95M | $52.09M | $52.89M | $53.19M | $52.30M | $20.88M | $32.09M |
| High Forecast | $84.14M | $80.90M | $76.38M | $70.50M | $76.98M | $76.74M | $72.44M | $136.20M | $76.95M | $71.15M | $72.07M | $123.81M | $73.89M | $83.95M | $79.89M | $112.56M | $75.44M | $69.17M | $65.91M | $102.33M | $71.16M | $63.76M | $48.07M | $32.34M | $52.09M | $52.89M | $53.19M | $62.76M | $25.06M | $38.51M |
| Low Forecast | $79.31M | $76.25M | $72.00M | $67.57M | $74.07M | $76.43M | $72.44M | $90.80M | $74.13M | $71.14M | $67.93M | $82.54M | $49.26M | $83.95M | $79.89M | $75.04M | $75.44M | $69.17M | $65.91M | $68.22M | $71.16M | $63.76M | $48.07M | $21.56M | $52.09M | $52.89M | $53.19M | $41.84M | $16.70M | $25.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 1.24% | 0.83% | 1.20% | 1.34% | 1.26% | 0.96% | 1.35% | 1.04% | 1.05% | 0.72% | 0.79% | 0.86% | 1.00% | 1.59% | 0.69% | 0.77% | 0.77% | 0.78% | 1.76% | 0.88% |
Supernus Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $75.46M, based on 3 Wall Street analysts, with a range of $74.13M to $76.95M. The forecast indicates a -8.76% fall compared to SUPN last annual SG&A of $82.70M (Sep 23).
Supernus Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.29 | $-0.02 | $0.31 | $0.47 | $0.03 | $0.15 | $0.48 | $0.05 | $0.41 | $0.45 | $0.11 | $0.58 | $0.76 | $0.66 | $0.41 | $0.63 | $0.55 | $0.62 | $0.35 | $0.51 | $0.21 |
| Avg Forecast | $0.55 | $0.51 | $0.44 | $0.39 | $0.50 | $0.44 | $0.39 | $0.38 | $0.55 | $0.01 | $0.21 | $0.31 | $0.67 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.19 | $0.25 |
| High Forecast | $0.57 | $0.53 | $0.45 | $0.43 | $0.55 | $0.45 | $0.41 | $0.39 | $0.59 | $0.01 | $0.22 | $0.32 | $0.70 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.22 | $0.30 |
| Low Forecast | $0.53 | $0.49 | $0.42 | $0.36 | $0.45 | $0.44 | $0.38 | $0.36 | $0.51 | - | $0.20 | $0.30 | $0.65 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.15 | $0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | -58.00% | -0.07% | 1.01% | 0.70% | 0.08% | 0.52% | 1.51% | 0.16% | 1.48% | 1.86% | 0.38% | 1.03% | 2.19% | 1.51% | 1.52% | 1.06% | 0.90% | 1.04% | 0.74% | 2.68% | 0.84% |
According to 1 Wall Street analysts, Supernus Pharmaceuticals's projected average Quarter EPS for Jun 23 is $0.21, with a low estimate of $0.20 and a high estimate of $0.22. This represents a -32.26% decrease compared to SUPN previous annual EPS of $0.31 (Mar 23).
Supernus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $17.38 | $35.00 | 101.38% | Hold |
| EVO | Evotec SE | $5.35 | $8.00 | 49.53% | Buy |
| ANIP | ANI Pharmaceuticals | $55.86 | $79.00 | 41.42% | Buy |
| COLL | Collegium Pharmaceutical | $30.41 | $40.50 | 33.18% | Buy |
| PBH | Prestige Consumer Healthcare | $84.14 | $89.50 | 6.37% | Buy |
| SUPN | Supernus Pharmaceuticals | $35.82 | $38.00 | 6.09% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $23.76 | $18.67 | -21.42% | Buy |